Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome-Reference-Cited by-同舟云学术

Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome

Published:2015-07-06 Issue:7 Volume:10 Page:e0132561
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wei You-quan,Wang Dian-gang,Yang Hao,Cao Heng

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference19 articles.

1. Individual variations of platelet inhibition after loading doses of clopidogrel;P Järemo;J Intern Med,2002

2. Variability in platelet responsiveness to clopidogrel among 544 individuals;VL Serebruany;J Am Coll Cardiol,2005

3. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite;M Kazui;Drug Metab Dispos,2010

4. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects;JS Hulot;Blood,2006

5. Inhibition of platelet aggregation by clopidogrel is unaffected by the CYP2C19 681G > A polymorphism in patients with coronary artery disease (abstr);SMG Smith;J Am Coll Cardiol,2007

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of loss-of-function CYP2C19 variants on clinical outcomes in coronary artery disease patients treated with clopidogrel: A systematic meta-analysis approach;International Journal of Cardiology;2024-11

2. Pharmacogenetics of Antiplatelet Therapy;Annual Review of Pharmacology and Toxicology;2023-01-20

3. Antiplatelet response to clopidogrel is associated with a haplotype in CYP2C19 gene in Pakistani patients;Scientific Reports;2022-04-13

4. Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis;Pharmacogenomics;2022-02

5. Personalized medicine in non-communicable diseases: latest advances and future prospects;Kardiologiia;2021-11-30